Attached files

file filename
8-K - CURRENT REPORT ON FORM 8-K - PETMED EXPRESS INCpets012312_8k.htm


Exhibit 99.1

PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES ITS THIRD QUARTER FINANCIAL RESULTS

Net Sales Increased 12% to $50.5 Million

New Order Sales Increased 29% to $10.1 Million

Online Sales Increased 19% to $38.7 Million

Pompano Beach, Florida, January 23, 2012 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended December 31, 2011.  Net sales for the quarter ended December 31, 2011 were $50.5 million, compared to $45.1 million for the quarter ended December 31, 2010, an increase of 12%.  Net sales for the nine months ended December 31, 2011 were $182.3 million, compared to $180.7 million for the nine months ended December 31, 2010, an increase of 1%.  Net income was $3.9 million or $0.19 diluted per share for the quarter ended December 31, 2011, compared to net income of $4.5 million or $0.20 diluted per share for the quarter ended December 31, 2010, a 3% decrease to EPS.  For the nine months ended December 31, 2011, net income was $12.7 million or $0.61 diluted per share, compared to net income of $16.7 million or $0.74 diluted per share for the nine months ended December 31, 2010, a decrease to earnings per share of 17%.  New order sales increased by 29%, from $7.8 million to $10.1 million for the quarters ended December 31, 2010 and 2011, respectively.  New order sales for the nine months ended December 31, 2011 were $39.8 million, compared to $37.9 million for the nine months ended December 31, 2010, an increase of 5%.  


Menderes Akdag, President and CEO, commented: “We are pleased to report that we acquired 150,000 new customers in the quarter ended December 31, 2011, compared to 111,000 new customers acquired for the same period in the prior year, a 35% increase.  Our advertising cost to acquire a new customer decreased by 11% to $36 for the quarter ended December 31, 2011, compared to $40 for the same period in the prior year.  We are also pleased to report that our online sales increased by 19% to $38.7 million for the quarter, compared to $32.4 million for the same quarter the prior year, with approximately 77% of our orders being generated from our website during the quarter, compared to 72% in the same quarter in the prior year.  Our reorder sales increased by 8% to $40.5 million for the quarter compared to $37.3 million for the same quarter the prior year.  During the quarter, the Company leveraged its operating expenses as a percent of sales, by 92 basis points as compared to the same quarter in the prior year. Going forward, we will continue to advertise aggressively while expanding our product offerings, which include generic pet medications.”


This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter’s financial results.  To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (210) 234-0009.  Callers will be required to supply PETMEDS as the passcode.  For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. Eastern Time on January 23, 2012 until February 6, 2012 at 10:59 P.M. Eastern Time.  To access the replay, call (888) 562-3875 (toll free) or (203) 369-3173, and enter passcode 5500.


Founded in 1996, PetMed Express is America’s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.


This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan.  Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2011.  The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.  For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 954-979-5995.


###



Exhibit 99.1 Page 1 of 4



PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


 

 

December 31,

 

March 31,

 

 

2011

 

2011

 

 

(Unaudited)

 

 

ASSETS

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

   Cash and cash equivalents

$

41,965

$

49,660 

   Short term investments - available for sale

 

10,300

 

10,116 

   Accounts receivable, less allowance for doubtful

 

 

 

 

      accounts of $5 and $6, respectively

 

1,639

 

1,985 

   Inventories - finished goods

 

25,946

 

25,140 

   Prepaid expenses and other current assets

 

2,013

 

1,036 

   Deferred tax assets

 

1,216

 

1,003 

   Prepaid income taxes

 

102

 

664 

          Total current assets

 

83,181

 

89,604 

 

 

 

 

 

   Long term investments

 

1,480

 

12,390 

   Property and equipment, net

 

2,882

 

3,433 

   Intangible asset

 

860

 

860 

 

 

 

 

 

Total assets

$

88,403

$

106,287 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

   Accounts payable

$

6,141

$

6,452 

   Accrued expenses and other current liabilities

 

2,090

 

2,509 

          Total current liabilities

 

8,231

 

8,961 

 

 

 

 

 

Deferred tax liabilities

 

359

 

321 

 

 

 

 

 

Total liabilities

 

8,590

 

9,282 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

   Preferred stock, $.001 par value, 5,000 shares authorized;

 

 

 

 

      3 convertible shares issued and outstanding with a

 

 

 

 

      liquidation preference of $4 per share

 

9

 

   Common stock, $.001 par value, 40,000 shares authorized;

 

 

 

 

      20,338 and 22,331 shares issued and outstanding, respectively

 

20

 

22 

   Retained earnings

 

79,774

 

97,115 

   Accumulated other comprehensive gain (loss)

 

10

 

(141)

 

 

 

 

 

          Total shareholders' equity

 

79,813

 

97,005 

 

 

 

 

 

Total liabilities and shareholders' equity

$

88,403

$

106,287 




Exhibit 99.1 Page 2 of 4




PETMED EXPRESS, INC. AND SUBSIDIARIES

 CONDENSED CONSOLIDATED STATEMENTS OF INCOME

 (In thousands, except for per share amounts) (Unaudited)


 

 

 Three Months Ended

 

 Nine Months Ended

 

 

 December 31,

 

 December 31,

 

 

2011

 

2010

 

2011

 

2010

 

 

 

 

 

 

 

 

 

 Sales

 $

50,523 

 $

45,118 

 $

182,326

 $

180,732 

 Cost of sales

 

33,369 

 

28,193 

 

121,128

 

114,251 

 

 

 

 

 

 

 

 

 

 Gross profit

 

17,154 

 

16,925 

 

61,198

 

66,481 

 

 

 

 

 

 

 

 

 

 Operating expenses:

 

 

 

 

 

 

 

 

      General and administrative

 

5,244 

 

5,096 

 

16,952

 

17,017 

      Advertising

 

5,449 

 

4,444 

 

23,453

 

21,859 

      Depreciation

 

359 

 

358 

 

1,046

 

1,023 

 Total operating expenses

 

11,052 

 

9,898 

 

41,451

 

39,899 

 

 

 

 

 

 

 

 

 

 Income from operations

 

6,102 

 

7,027 

 

19,747

 

26,582 

 

 

 

 

 

 

 

 

 

 Other income (expense):

 

 

 

 

 

 

 

 

      Interest income, net

 

70 

 

98 

 

228

 

265 

      Other, net

 

(1)

 

(144)

 

62

 

(111)

 Total other income (expense)

 

69 

 

(46)

 

290

 

154 

 

 

 

 

 

 

 

 

 

 Income before provision for income taxes

 

6,171 

 

6,981 

 

20,037

 

26,736 

 

 

 

 

 

 

 

 

 

 Provision for income taxes

 

2,273 

 

2,459 

 

7,372

 

10,011 

 

 

 

 

 

 

 

 

 

 Net income

 $

3,898 

 $

4,522 

 $

12,665

 $

16,725 

 

 

 

 

 

 

 

 

 

 Net income per common share:

 

 

 

 

 

 

 

 

       Basic

 $

0.19 

 $

0.20 

 $

0.61

 $

0.74 

       Diluted

 $

0.19 

 $

0.20 

 $

0.61

 $

0.74 

 

 

 

 

 

 

 

 

 

 Weighted average number of common shares outstanding:

 

 

 

 

 

 

       Basic

 

20,082

 

22,506

 

20,788

 

22,614

       Diluted

 

20,180

 

22,655

 

20,886

 

22,755

 

 

 

 

 

 

 

 

 

 Cash dividends declared per common share

 $

0.125

 $

0.125

 $

0.375

 $

0.350




Exhibit 99.1 Page 3 of 4



PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)


 

 

 Nine Months Ended

 

 

 December 31,

 

 

2011

 

2010

 Cash flows from operating activities:

 

 

 

 

    Net income

 $

12,665 

 $

16,725 

    Adjustments to reconcile net income to net cash

 

 

 

 

     provided by operating activities:

 

 

 

 

        Depreciation

 

1,046 

 

1,023 

        Share based compensation

 

1,686 

 

1,606 

        Deferred income taxes

 

(175)

 

202 

        Bad debt expense

 

40 

 

30 

        (Increase) decrease in operating assets

 

 

 

 

           and increase (decrease) in liabilities:

 

 

 

 

             Accounts receivable

 

306 

 

1,265 

             Inventories - finished goods

 

(806)

 

14,179 

             Prepaid income taxes

 

562 

 

(541)

             Prepaid expenses and other current assets

 

(977)

 

(1,238)

             Accounts payable

 

(182)

 

(1,532)

             Accrued expenses and other current liabilities

 

(443)

 

(246)

 Net cash provided by operating activities

 

13,722 

 

31,473 

 

 

 

 

 

 Cash flows from investing activities:

 

 

 

 

    Net change in investments

 

10,877 

 

(10,104)

    Purchases of property and equipment

 

(624)

 

(491)

    Purchases of intangible asset

 

 

(10)

 Net cash provided by (used in) investing activities

 

10,253 

 

(10,605)

 

 

 

 

 

 Cash flows from financing activities:

 

 

 

 

    Dividends paid

 

(7,914)

 

(7,933)

    Purchases of treasury stock

 

(23,685)

 

(5,225)

    Tax adjustment related to restricted stock

 

(71)

 

25 

    Proceeds from the exercise of stock options

 

 

252 

    Tax benefit related to stock options exercised

 

 

124 

 Net cash used in financing activities

 

(31,670)

 

(12,757)

 

 

 

 

 

 Net (decrease) increase in cash and cash equivalents

 

(7,695)

 

8,111 

 Cash and cash equivalents, at beginning of period

 

49,660 

 

53,143 

 

 

 

 

 

 Cash and cash equivalents, at end of period

 $

41,965 

 $

61,254 

 

 

 

 

 

 Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

    Cash paid for income taxes

 $

7,056 

 $

10,254 

 

 

 

 

 

    Property and equipment purchases in accounts payable

 $

 $

259 

 

 

 

 

 

    Dividends payable in accrued expenses

 $

167 

 $

126 




Exhibit 99.1 Page 4 of 4